Pharmaniaga posts steady Q1 profit, to expand vaccine business as Covid-19 rages   

KUALA LUMPUR: Pharmaniaga Bhd said revenue from its Sinovac Covid-19 business to start coming in from the June quarter onwards.

"The distribution of the first batch of 290,480 doses of the vaccine to the market has commenced on May 11," the company said in a filing with Bursa Malaysia today.

"As one of the largest pharmaceutical companies in Malaysia, the Group is focused on the supply and distribution of Covid-19 vaccines, which are expected to persist given new waves of cases around the world," it added.

Pharmaniaga, in March, has entered into a deal China-based Sinovac Biotech Ltd to manufacture Covid-19 vaccines in Malaysia.

The company, on Thursday, posted a net profit of RM23.1mil, or 8.8 sen a share in the first quarter ended March 31.

It has declared an interim dividend payout of 4 sen a share.

"As part of the long-term sustainable growth plans, the Group aims to accelerate the growth of the vaccine manufacturing business by embarking on a Halal vaccine project," Pharmaniaga said.

"This will see the Group establishing the world’s first Halal vaccine facility, which is targeted for completion by 2024, creating a new income stream," it added.

Article type: metered
User Type: anonymous web
User Status:
Campaign ID: 1
Cxense type: free
User access status: 0
Subscribe now to our Premium Plan for an ad-free and unlimited reading experience!

Pharmaniaga , Sinovac , Vaccine


Next In Business News

CPO futures likely to trade with downward bias next week
Rupee erases gains on banking worries
MSMEs still at early stage of digitalisation
The global game of ChessGo
Banks remain on the radar
KAB looking to boost earnings via PetGas sustainable energy JV
Are our banks safe?
Vivek Sood appointed as Axiata CEO, MD
Fed’s dovish slant forecast to buoy the ringgit
Short Position: Break-up pays, Hap Seng's RPT

Others Also Read